Zhi-Qiao Liang1,2,3,4, Lyu-Zhen Huang1,2,3,4, Jin-Feng Qu1,2,3,4, Ming-Wei Zhao1,2,3,4. 1. Department of Ophthalmology, Peking University People's Hospital, Beijing 100044, China. 2. Eye Diseases and Optometry Institute, Beijing 100044, China. 3. Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China. 4. College of Optometry, Peking University Health Science Center, Beijing 100044, China.
Abstract
AIM: To assess the association between endogenous cortisol level and the risk of central serous chorioretinopathy (CSC). METHODS: Case-control studies were systematically searched on PubMed, Embase, Cochrane, China National Knowledge Infrastructure (CNKI) for publishes between January 1990 and July 2017 to assess the association between endogenous cortisol level and CSC. The main endpoints were serum cortisol level at 8 a.m. and 24-hour urine 17-hydroxysteroids level. We assessed pooled data using a random-effects model. RESULTS: Of 86 identified studies, 5 were eligible included in our analysis. The 5 studies included a total of 315 participants, of whom 187 had CSC. Statistically significant association was observed between serum cortisol level (summary SMD=0.77, 95%CI=0.55-0.99), 24-hour urine 17-hydroxysteroids level (summary SMD=0.95, 95%CI=0.61-1.30), and the risk of CSC. CONCLUSION: Endogenous cortisol level is associated with an increased risk of CSC. Combined treatment targeting the serum cortisol level at 8 a.m. and 24-hour urine 17-hydroxysteroids level can be a potential preventive strategy for individuals who are at risk of CSC and therapeutic strategy for patients with CSC.
AIM: To assess the association between endogenous cortisol level and the risk of central serous chorioretinopathy (CSC). METHODS: Case-control studies were systematically searched on PubMed, Embase, Cochrane, China National Knowledge Infrastructure (CNKI) for publishes between January 1990 and July 2017 to assess the association between endogenous cortisol level and CSC. The main endpoints were serum cortisol level at 8 a.m. and 24-hour urine 17-hydroxysteroids level. We assessed pooled data using a random-effects model. RESULTS: Of 86 identified studies, 5 were eligible included in our analysis. The 5 studies included a total of 315 participants, of whom 187 had CSC. Statistically significant association was observed between serum cortisol level (summary SMD=0.77, 95%CI=0.55-0.99), 24-hour urine 17-hydroxysteroids level (summary SMD=0.95, 95%CI=0.61-1.30), and the risk of CSC. CONCLUSION: Endogenous cortisol level is associated with an increased risk of CSC. Combined treatment targeting the serum cortisol level at 8 a.m. and 24-hour urine 17-hydroxysteroids level can be a potential preventive strategy for individuals who are at risk of CSC and therapeutic strategy for patients with CSC.
Authors: Carl Schubert; Anders Pryds; Shemin Zeng; Yajing Xie; K Bailey Freund; Richard F Spaide; John C Merriam; Irene Barbazetto; Jason S Slakter; Stanley Chang; Inger C Munch; Arlene V Drack; Jasmine Hernandez; Suzanne Yzer; Joanna E Merriam; Allan Linneberg; Michael Larsen; Lawrence A Yannuzzi; Robert F Mullins; Rando Allikmets Journal: Hum Mutat Date: 2014-07 Impact factor: 4.700